Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
about
Mutational profiling of kinases in glioblastoma.Recurrent Glioblastoma: Where we standNonsurgical treatment of recurrent glioblastomaThe Role of End-of-Life Issues in the Design and Reporting of Cancer Clinical Trials: A Structured Literature ReviewMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateDeregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targetsMedical management of brain tumors and the sequelae of treatment.Recent advancements in multimodality treatment of gliomasNovel delivery strategies for glioblastomaTumor treating fields: a novel treatment modality and its use in brain tumorsGlioblastoma multiforme: emerging treatments and stratification markers beyond new drugsHow can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies.It is time to include patients with brain tumors in phase I trials in oncologyDrug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastomaSalvage therapy with single agent bendamustine for recurrent glioblastoma.A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma.EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.A phase II trial of oral gimatecan for recurrent glioblastoma.A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.Combinatorial inhibition of Plk1 and PKCĪ² in cancer cells with different p53 statusPatterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.Molecular targeting of glioblastoma: Drug discovery and therapiesCentral nervous system cancersExperimental approaches for the treatment of malignant gliomas.Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.Defective p53 antiangiogenic signaling in glioblastoma.Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocolMedical therapy of gliomas.Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).Impact of imaging measurements on response assessment in glioblastoma clinical trialsRetrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.Antiangiogenic therapy for glioblastoma: current status and future prospects.Towards personalized therapy for patients with glioblastoma.Pathway inhibition: emerging molecular targets for treating glioblastoma.
P2860
Q21261249-1F73A11C-EE50-45E2-8A8B-84F468C63F84Q26765042-E7ECA8EC-846F-481C-896B-0A2BE47C390CQ26795560-ADFC6D7A-B7FB-4082-84C3-24867B163105Q26795613-6BE404AC-381F-45AE-88C9-79C260CC9069Q26822717-78A55062-4598-4660-A0B3-4D7159D1B1F5Q26829873-B63DE841-24C5-4087-BF64-B94E0EE1B86BQ26992174-4BDB2C3A-10DA-4555-8B8F-D8CE1BC65DCDQ27001724-DBD1076F-CC0C-428F-A268-317DD6C4542DQ27006099-18A0D03E-08D1-4910-B97A-656E2D0C0BC7Q28073779-514FCF52-8266-4DC9-8D11-F6D8733E4B20Q28082603-E3413024-8E6E-42A2-9428-90261E0AA6E8Q30252700-3AEAC6FE-6A8D-4ABE-93A4-45DFAD0C8343Q30359570-ED1E79D6-6946-4C81-BA45-3A1EB61E4D86Q30616602-5BA602EF-AC7D-49EC-9E99-F4E54D87F546Q30661157-26D5C01C-4151-44F0-84D5-B07CD2E44182Q33395579-24681C73-CB1D-41B0-AEEB-F1A5D5CFEEE8Q33399406-18EB337D-F80A-4525-889D-732856BC1CF7Q33402044-2B71BB9E-093A-43BE-9B74-253E8EDFA645Q33402531-E2382858-8854-4D82-A4D1-DA905C378363Q33403967-AE10A5A6-932D-4360-88A9-D6AD071C02ACQ33404780-1EE35FAA-A967-47EB-93EA-3661E6E4782BQ33418912-FC73420E-1128-4847-B49D-10A9FCCE6A8FQ33419628-6494C9DE-8C20-42C6-B6E5-B14FCC6FDA26Q33688600-0F9B1239-FDD2-449E-A3FA-6576F2C38E66Q33807228-448EF16C-68BE-4F94-8AEA-BEABA484D313Q33869702-3AE47D32-3E23-4DF4-B2D3-C3AD519A3A71Q33911283-9035DFC2-39F5-47EC-919B-E7D8A6DBB8A3Q34014740-45E17D05-FE6E-46EC-9224-4D1ACE74B3BCQ34127138-C86D9CF8-CD86-4AF5-9C13-048AE05E8AD1Q34132781-A423EBF0-03E6-4331-8CD3-5C32EAD3A44CQ34133118-48FCDC51-6279-4697-A757-454A34F8A50AQ34205208-71CAE30E-DE15-41F0-9FB6-0735ADB20ECAQ34218761-803EC859-A656-4132-BA0F-512A7C4AD73DQ34331320-1233CA9B-3AE6-4D03-BBDE-6D5FA259414CQ34331328-898568B1-9979-4BC3-81CC-36176649979CQ34359710-93FCE091-F33C-4021-A23D-05EA481699A2Q34480495-C774DAFE-366A-4B42-8E60-8A06C63A0E8AQ34523319-FD0C7143-71C1-4CBE-9545-2071E2B2013EQ34978252-EEFF2221-A825-4AC2-8106-B2A522BFF956Q35021359-E820C8E0-91B1-4F0A-930F-AF3962F322E4
P2860
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
description
2010 nĆ® lÅ«n-bĆ»n
@nan
2010 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ„ÕæÖÕøÖÕ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2010 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« ÖÕ„ÕæÖÕ¾Õ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2010幓ć®č«ę
@ja
2010幓č«ę
@yue
2010幓č«ę
@zh-hant
2010幓č«ę
@zh-hk
2010幓č«ę
@zh-mo
2010幓č«ę
@zh-tw
2010幓č®ŗę
@wuu
name
Phase III study of enzastaurin ...... ent intracranial glioblastoma.
@ast
Phase III study of enzastaurin ...... ent intracranial glioblastoma.
@en
type
label
Phase III study of enzastaurin ...... ent intracranial glioblastoma.
@ast
Phase III study of enzastaurin ...... ent intracranial glioblastoma.
@en
prefLabel
Phase III study of enzastaurin ...... ent intracranial glioblastoma.
@ast
Phase III study of enzastaurin ...... ent intracranial glioblastoma.
@en
P2093
P2860
P356
P1476
Phase III study of enzastaurin ...... ent intracranial glioblastoma.
@en
P2093
Antoine F Carpentier
Astra M Liepa
Donald E Thornton
Howard A Fine
Lawrence M Cher
Luna Musib
Marc C Chamberlain
Martin J van den Bent
Shengyan Hong
Vinay K Puduvalli
P2860
P304
P356
10.1200/JCO.2009.23.2595
P407
P577
2010-02-01T00:00:00Z